BrightGene's obesity shot BGM0504 posts strong Phase 3 data in China as it courts a Western partner ahead of a planned global trial.
Armed with impressive Phase 3 data, BrightGene is taking its obesity shot to Chinese regulators. It expects trial data in the West to be even …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Novo Nordisk targets a ~2030 launch for UBT251, a triple-G obesity drug showing up to 19.7% weight loss in a China Phase 2.
Sciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is…
US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and…
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen…
The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side…
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
